Icosavax Provides Corporate Update and Anticipated Milestones for 2023
06 janv. 2023 08h00 HE
|
Icosavax, Inc.
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of...
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
06 janv. 2023 07h15 HE
|
BiondVax Pharmaceuticals Ltd.
Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those treated...
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
14 déc. 2022 08h30 HE
|
Dyadic International, Inc.
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19
30 nov. 2022 15h01 HE
|
POP Biotechnologies
BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a Buffalo, New York-based biopharmaceutical startup, announces the publication of an interim analysis of the Phase 2...
BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy
29 nov. 2022 07h00 HE
|
BiondVax Pharmaceuticals Ltd.
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with...
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
17 nov. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable safety profile in both the single-ascending dose and...
APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
03 nov. 2022 03h00 HE
|
invIOs GmbH
Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2Investigators recommend further development of inhaled APN01, which may...
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
27 oct. 2022 09h04 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
26 oct. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a Phase 1 healthy volunteer study to assess the safety, tolerability...
Cocrystal Pharma to Present at the LD Micro Main Event XV
19 oct. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-interim CEO Sam Lee, PhD will present a company overview of their antiviral...